Research Papers:

Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma

Xiong Lei, Yun-feng Li, Guo-dong Chen, Di-peng Ou, Xiao-xin Qiu, Chao-hui Zuo and Lian-Yue Yang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:40622-40641. https://doi.org/10.18632/oncotarget.5872

Metrics: PDF 2745 views  |   HTML 2483 views  |   ?  


Xiong Lei1,*, Yun-feng Li1,*, Guo-dong Chen1, Di-peng Ou2, Xiao-xin Qiu3, Chao-hui Zuo3, Lian-Yue Yang1,2

1Liver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China

2Department of Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China

3Department of Abdominal Surgical Oncology, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, China

*These authors have contributed equally to this work

Correspondence to:

Lian-Yue Yang, e-mail: [email protected]

Keywords: Ack1, hepatocellular carcinoma, prognosis, metastasis

Received: May 11, 2015     Accepted: September 28, 2015     Published: October 20, 2015


Despite the substantial data supporting the oncogenic role of Ack1, the predictive value and biologic role of Ack1 in hepatocellular carcinoma (HCC) metastasis remains unknown. In this study, both correlations of Ack1 expression with prognosis of HCC, and the role of Ack1 in metastasis of HCC were investigated in vitro and in vivo. Our results showed that Ack1 was overexpressed in human HCC tissues and cell lines. High Ack1 expression was associated with HCC metastasis and determined as a significant and independent prognostic factor for HCC after liver resection. Ack1 promoted HCC invasion and metastasis in vitro and in vivo. Mechanistically, we confirmed that Ack1 enhanced invasion and metastasis of HCC via EMT by mediating AKT phosphorylation. In conclusion, our study shows Ack1 is a novel prognostic biomarker for HCC and promotes metastasis of HCC via EMT by activating AKT signaling.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5872